Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)
Authors:
- Jan van LunzenJLJan van Lunzen
- Michael WestbyMWMichael Westby
- Eithne O'SUllivanEOEithne O'SUllivan
- Claus SchneiderCSClaus Schneider
- Axel AdamAAAxel Adam
- Lutwin WeitnerLWLutwin Weitner
- Birger KuhlmannBKBirger Kuhlmann
- Christian HoffmannCHChristian Hoffmann
- Stefan FenskeSFStefan Fenske
- Philipp S. AriesPAPhilipp S. Aries
- Olaf DegenODOlaf Degen
- 1 July 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (11) , 1479-1487
Abstract
The effect of interleukin-2 (IL-2) in combination with antiretroviral therapy on HIV-1 replication and reservoirs was investigated. In a prospective, open-label trial, 56 asymptomatic HIV-1-infected subjects (CD4 T cell count > 350 × 106 cells/l) were randomized to highly active antiretroviral therapy (HAART: stavudine, lamivudine, nelfinavir, saquinavir) with or without IL-2 (9 megaunits daily for 5 days in 6-weekly intervals for a total of eight cycles). Productive and latent infection were analysed in peripheral blood, and residual virus replication in the lymphoid tissue and in the cerebrospinal fluid. The influence of IL-2 on viral rebound after treatment discontinuation was studied. Virus replication was detected in 21 of 31 on-treatment lymph nodes despite undetectable plasma viraemia. Viral RNA was found in resting as well as in proliferating cells. RNA-negative patients tended towards more rapid proviral DNA elimination. Supplementary IL-2 led to a greater increase in CD4 T cell counts than HAART alone (P < 0.001), resulting in normalization in ~90% of IL-2-treated patients compared with ~50% HAART-only subjects. IL-2 had no beneficial effect on virus replication and on proviral DNA in peripheral blood. Viral persistence during HAART is partly a result of continued low-level replication, calling for more active regimens. IL-2 accelerates the normalization of CD4 T cell counts but does not impact on virus production or latency.Keywords
This publication has 41 references indexed in Scilit:
- Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4 + T CellsScience, 1999
- Efficacy of Low‐Dose Subcutaneous Interleukin‐2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with ⩽250/μL CD4 T Cells and Undetectable Plasma Virus LoadThe Journal of Infectious Diseases, 1999
- Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2AIDS, 1999
- Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects.Journal of Clinical Investigation, 1997
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Immunohistochemical, electron microscopic and in situ hybridization evidence for the involvement of lymphatics in the spread of HIV-1AIDS, 1988
- Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.Journal of Clinical Investigation, 1983